Our Research Let’s take a look.
Our department pursues research in pharmacology and therapeutics in a wide variety of ways. Delve into some of our various labs below:
- Each of these areas is closely interwoven with the subject matter and experimental techniques of physiology, biochemistry, cellular and molecular biology, microbiology, immunology, genetics, and pathology.
- A significant number of faculty are actively involved in new drug development and discovery, while many others are vigorously involved in the development of biological therapies.
- Extramural research support is provided from federal, private, and industrial sources to foster new discoveries in both molecular and systems pharmacology.
- The department has a strong commitment to the education of students in order to understand and apply the principles of pharmacology and therapeutics to train them in multidisciplinary research.
The Wesson Lab
On his website, Dan Wesson, Ph.D., says, “Here in the Wesson Lab, we explore the neural processing of sensory information in the context of behavior. ”
The Bird Lab
The Bird Lab is interested in how myosin molecular motors generate force on actin filaments and how defects in this fundamental cytoskeletal mechanism cause human disease. Dr. Bird studies this question using hair cells, the neural receptors for hearing and balance that are found within the inner ear.
The Casadesus Lab
The main goal of Dr. Casadesus’ Research program is to understand how, at a cellular and molecular level, age-related or lifestyle-mediated changes in hormones receptor signaling impact brain health and drive increased risk for AD.
The Chapman Lab
The Chapman Lab is a chemical biology lab that focuses on the discovery and development of small-molecule modulators of cellular quality control machinery. These compounds are used to answer biological questions, to validate potential therapeutic targets, and as possible therapeutic leads. There are three primary areas of focus: 1) The discovery and development of isoform selective HSP70 inhibitors as potential cancer therapeutics. 2) The development of HSP60/10 inhibitors as cancer therapeutics and GroEL/ES (the bacterial HSP60/10) inhibitors as antibiotics. 3) The discovery and development of NRF2 activators as chemopreventive compounds and NRF2 inhibitors as cancer therapeutics.
The Guryanova Lab
Meet Olga Guryanova, M.D., Ph.D., assistant professor, and learn about her research on chromatin organization and epigenetic regulation on leukemia development.
The Hammers Lab
The Hammers Lab researches physiological and pathophysiological mechanisms of skeletal and cardiac muscle, particularly those associated with genetic diseases known as muscular dystrophies. The primary motivation of these efforts is to identify potential therapeutic targets that can be exploited to develop treatments for muscle and heart diseases using small molecules and/or adeno-associated virus (AAV)-based gene therapies.
The Harrison Lab
Efforts in Dr. Harrison’s laboratory are directed toward understanding mechanisms by which immune cells contribute to tumor progression and resistance to immunotherapies.
The May Khanna Lab
The May Khanna Lab is dedicated to the development of preclinical small molecule drugs for these diseases, bridging academia and industry to accelerate drug discovery.
The Raj Khanna Lab
The Raj Khanna lab studies allosteric regulation and trafficking of voltage-gated ion channels in chronic pain and neurodegenerative diseases. We are well-positioned to address broader foundational aspects of the chronification of pain, with multidisciplinary expertise in mouse genetics, confocal microscopy, protein biochemistry, electrophysiology – i.e. whole cell (current- and voltage-clamp; in rats, mice, pigs, macaque, and human DRGs) and slice (mice and rats), live imaging and evoked/affective pain behavioral analyses in rodent models to dissect mechanisms and roles of chronic pain.
The Kopinke Lab
As stated on his website, Daniel Kopinke’s lab deals with defects in primary cilia can result in a wide range of diseases, referred to as “ciliopathies.”
The Law Lab
The Law Lab researches mechanisms by which CDCP1 Promotes Breast Cancer Metastasis: The CDCP1 protein functions as a scaffold to bring together and facilitate synergy between the oncoproteins Epidermal Growth Factor Receptor (EGFR) and the Src tyrosine kinase.
The Moehle Lab
The Moehle Lab is interested in understanding the physiological, circuitry, and behavioral changes that cause the motor and non-motor symptoms of movement disorders and then translate these findings into novel therapeutics for these disorders.
The Oliveira Lab
In the Oliveira Lab we are dedicated to understanding the brain’s pathogenic contribution to cardiopulmonary diseases, with a particular emphasis on pulmonary hypertension (PH). Our research aims to identify innovative therapeutic targets that could transform the treatment landscape for this debilitating condition.
The Russ Lab
The emphasis of the Russ lab is on developing innovative regenerative medicine approaches with a focus on understanding the underlying molecular and cellular mechanisms resulting in autoimmune type 1 diabetes (T1D) in humans.
The Sweeney Lab
Much of the Sweeney Lab’s research program is translational in focus, and has produced highly cited research on inherited forms of cardiovascular disease, and on the skeletal and cardiac aspects of muscular dystrophy. Currently the lab is focused on AAV gene therapy for animal models of Duchenne muscular dystrophy and small molecule therapies to augment the gene therapy.
The Urs Lab
The goals of our lab are to identify and map neuronal circuits that regulate dopamine signaling, motivation, movement and reward, by using state of the art tools such as viral tracing, opto/chemogenetics, fiber photometry, and operant behavioral conditioning.